Tg Therapeutics, Inc.TGTX

TG Therapeutics’ last filing reads like a mixed review of a blockbuster drug still searching for blockbuster economics: $204.9 million in quarterly revenue, $19.8 million in net income, and a share count that has quietly swollen to 160.1 million diluted shares. The company calls itself a leader in multiple sclerosis therapies through BRIUMVI (ublituximab), and it can point to positive Phase 3 ENHANCE results and fresh Phase 1 data for a subcutaneous formulation as proof the science is moving forward. Yet the same 10-Q that records those wins also shows a $17.9 million cash outflow from operations in the quarter and just $51,000 spent on property, plant, and equipment-numbers that look less like a growth story and more like a holding pattern dressed in clinical white coats.

BRIUMVI is the company’s only marketed product for relapsing multiple sclerosis, a disease where patients cycle through therapies and hope for fewer relapses. The drug’s label stresses effective contraception during and after treatment, a side note that quietly underscores the stakes: this is not a lifestyle pill. TG Therapeutics has been presenting BRIUMVI data at MS forums and trumpeting the subcutaneous formulation’s pharmacokinetic and safety profile, but the filing silence on pricing, market share, or prescription volume means investors are left guessing how many syringes are actually leaving the warehouse. The balance sheet carries $1.53 billion in assets against $945.7 million in liabilities, with equity at $583.1 million and $442.2 million in cash and equivalents-enough to keep the lights on, but not obviously enough to fund the next phase of clinical expansion without fresh capital or a partner. The company’s $129 million inventory build, up $13.3 million in the quarter, is either prudent stockpiling or a signal that demand isn’t yet matching supply.

The 10-Q for the quarter ending 31 March 2026 shows net income of $19.8 million on revenue of $204.9 million, operating income of $34.8 million, and diluted EPS of $0.12 on 160.1 million shares. Research and development expense was $48.4 million, more than double net income, while cash used in operations was $17.9 million. Short-term investments totalled $72.2 million, capex was $51,000, and inventories rose by $13.3 million. Assets stood at $1.53 billion, liabilities at $945.7 million, and equity at $583.1 million, with cash and cash equivalents at $442.2 million. The company held its 2026 annual meeting virtually on 12 June 2026. Positive Phase 1 data for subcutaneous BRIUMVI were announced on 3 June 2026, and positive topline results from the Phase 3 ENHANCE trial were announced on 27 May 2026. The company’s product page and MS forum presentations highlight BRIUMVI’s role in treating relapsing forms of multiple sclerosis.

For a stock that trades on the promise of a single drug franchise, the evidence trail is surprisingly thin on prescription dynamics. There is no filed disclosure of units shipped, payer coverage, or net revenue per prescription. The company’s investor materials highlight data presentations and clinical updates, but the SEC filings do not quantify commercial traction. That leaves the valuation tethered to clinical headlines rather than hard sales data-useful for conference-room theatrics, less useful for spreadsheet confidence.

The company’s SEC filings and press releases can be traced through the EDGAR index for CIK 0001001316, with the latest 10-Q filed for the quarter ending 31 March 2026. The company’s investor relations page and product site provide the public-facing narrative, while the EDGAR JSON endpoints capture the raw filing metadata. The official sources do not provide a chart route or trading levels; investors seeking price context should refer to their broker’s data feed or an exchange-provided charting service.

What changed in the last month: TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI on 3 June 2026 and positive topline Phase 3 ENHANCE results on 27 May 2026. The company’s 2026 annual meeting was held virtually on 12 June 2026. The last filed financials remain the 10-Q for the quarter ending 31 March 2026. There is no new revenue, EPS, or cash-flow disclosure since the prior filing.

What remains unproven: the scale of commercial uptake for BRIUMVI, the pricing power in a crowded MS market, and the speed at which the subcutaneous formulation can translate into materially improved cash flow. The company’s cash burn and inventory build suggest either prudent scaling or a commercial story still waiting to be told. Until filed disclosures quantify prescriptions, net revenue per script, and payer coverage, the valuation remains anchored to clinical headlines rather than hard commercial metrics.